Merck filled us in on its pipeline this morning as reported in GEN. The report was rosy for the combined pipeline of late stage candidates due to the addition of Schering-Plough. Merck reported more than 20 candidates in phase III or later stages of review, and another 20 in phase II. This is expected to fuel growth in the immediate future.
Elan Corp reported positive results on bapineuzumab in a phase II study in PBR. The drug currently being developed by Pfizer and J&J's sub Janssen (of which Elan holds a minority interest) reduced amyloid deposits in Alzheimer's patients.
The FDA gave final marketing approval to Shire's VPRIV for the treatment of Type I Gaucher's disease in pediatric and adult patients. See PBR article.
Finally, Serum Institute of India announced the initiation of a phase II trial with ErepoXen in India. EreproXen is a polysialylated form of EPO. SII is partnering with LipoXen, utilizing its PolyXen platform technology to link polysialic acid residues to protein molecules. See full report in PBR.